- Fund II
- €1B
- AuM
- €1.6B
Jeito Capital is a Paris-based biopharma investor that closed its second fund at €1 billion in April 2026 — the largest raise ever by a fully independent European biopharma fund. Jeito II backs 15–20 clinical-stage companies at up to €150 million each across oncology, obesity and autoimmune conditions, tripling the firm's assets under management to €1.6 billion against a falling global biotech VC market.